Author:
Harder J,Ihorst G,Heinemann V,Hofheinz R,Moehler M,Buechler P,Kloeppel G,Röcken C,Bitzer M,Boeck S,Endlicher E,Reinacher-Schick A,Schmoor C,Geissler M
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697
2. Bednar F, Simeone DM (2011) Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol 46: 1345–1352
3. Buechler P, Reber HA, Buechler MC, Roth MA, Buechler MW, Friess H, Isacoff WH, Hines OJ (2001) Therapy for pancreatic cancer with a recombinant humanized anti HER2 antibody (herceptin). J Gastrointest Surg 5: 139–146
4. Buechler P, Reber HA, Eibl G, Roth MA, Buechler MW, Friess H, Isacoff WH, Hines OJ (2005) Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 27: 1125–1130
5. Burris H, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
Cited by
158 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献